8-K Announcements
6Material company update
Mar 27, 2026·SEC
Material company update
Jan 12, 2026·SEC
Material company update
Jan 2, 2026·SEC
Vor Biopharma Inc.(VOR)Earnings, Financials & Key Ratios
VOR•NASDAQ
Price updated Jun 11, 2026
AboutVor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA-$369M-213.4%
- Net Income-$696M-495.3%
- EPS (Diluted)-70.50-107.4%
VOR Key Insights
Vor Biopharma Inc. (VOR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 74.2% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when VOR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VOR Price & Volume
Vor Biopharma Inc. (VOR) stock price & volume — 10-year historical chart
Loading chart...
VOR Growth Metrics
Vor Biopharma Inc. (VOR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-644.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2659.41%
Return on Capital
10 Years-406.8%
5 Years-68.57%
3 Years-86.84%
Last Year-131.97%
VOR Recent Earnings
Vor Biopharma Inc. (VOR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)
Q2 2026Latest
May 13, 2026EPS
$0.73
Est $0.75
+2.7%
Revenue
—
Q2 2026
Apr 2, 2026EPS
$82.04
Est $1.14
+7296.5%
Revenue
—
Q2 2026
Mar 30, 2026EPS
$44.50
Est $1.14
+4003.5%
Revenue
—
Q4 2025
Nov 13, 2025EPS
$3.33
Est $3.06
-8.8%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.73vs $0.75+2.7% | — |
| Q2 2026 | Apr 2, 2026 | $82.04vs $1.14+7296.5% | — |
| Q2 2026 | Mar 30, 2026 | $44.50vs $1.14+4003.5% | — |
| Q4 2025 | Nov 13, 2025 | $3.33vs $3.06-8.8% | — |
Based on last 12 quarters of dataView full earnings history →
VOR Peer Comparison
Vor Biopharma Inc. (VOR) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BEAM | 3.02B | 29.41 | -36.31 | 120.01% | -49.17% | -5.89% | 0.24 | |
 CRSP | 4.84B | 50.23 | -7.76 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 238.89M | 2.44 | -1.36 | 25.39% | -281.59% | -6.77% | 2.81 | |
 NTLA | 1.39B | 12.35 | -3.24 | 16.92% | -5.97% | -57.27% | 0.14 | |
 FATE | 229.62M | 1.97 | -1.71 | -51.24% | -20.57% | -58.89% | 0.38 | |
 CELC | 4.36B | 89.49 | -23.67 | -244.61% | 1.94 | |||
 SANA | 770.87M | 2.77 | -2.89 | -161.87% | 0.49 | |||
 SGMO | 62.14M | 0.15 | -0.34 | -31.57% | -356.89% | -28.92% |
Compare VOR vs Peers
Vor Biopharma Inc. (VOR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VOR Income Statement
Vor Biopharma Inc. (VOR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 20K | 91K | 0 | 0 | 8.96M | 3.49M | 0 | 0 | 28K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | -20K▲ 0% | -91K▼ 355.0% | 0▲ 100.0% | 0▲ 0% | -8.96M▲ 0% | -3.49M▲ 61.0% | 0▲ 100.0% | 0▲ 0% | -28K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | -355% | 100% | - | - | 61.03% | 100% | - | - |
Operating Expenses | 2.86M | 10.33M | 43.37M | 69.02M | 84.46M | 122.54M | 121.19M | 371.64M | 373.48M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 427K | 4.13M | 11.75M | 21.49M | 19.91M | 31.72M | 27.88M | 50.11M | 51.12M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
Research & Development | 2.43M | 6.2M | 31.62M | 47.53M | 64.55M | 94.31M | 93.31M | 321.53M | 312.43M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -3.49M | 0 | 0 | 549K |
Operating Income | -2.86M▲ 0% | -10.42M▼ 264.2% | -43.37M▼ 316.3% | -69.02M▼ 59.2% | -93.42M▼ 35.4% | -126.04M▼ 34.9% | -121.19M▲ 3.8% | -371.64M▼ 206.7% | -373.51M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -264.23% | -316.3% | -59.15% | -35.35% | -34.92% | 3.85% | -206.67% | - |
EBITDA | -2.84M | -10.33M | -42.76M | -67.58M | -84.46M | -122.54M | -117.66M | -368.75M | -371.42M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | -263.59% | -314.11% | -58.05% | -24.97% | -45.09% | 3.99% | -213.42% | -212.8% |
D&A (Non-Cash Add-back) | 20K | 91K | 605K | 1.43M | 8.96M | 3.49M | 3.53M | 2.89M | 2.09M |
EBIT | -3.15M | -10.23M | -43.37M | -69.02M | -92.09M | -117.86M | -121.19M | -371.64M | -1.13B |
Net Interest Income | 0 | -454K | 29K | 119K | 1.32M | 8.17M | 4.27M | 5.87M | 9M |
Interest Income | 0 | 154K | 29K | 119K | 1.32M | 8.17M | 4.27M | 5.87M | 9M |
Interest Expense | 1M | 608K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -1.29M | -422K | 29K | 119K | 1.32M | 8.17M | 4.27M | -324.34M | -509.57M |
Pretax Income | -4.15M▲ 0% | -10.84M▼ 161.1% | -43.34M▼ 299.8% | -68.9M▼ 59.0% | -92.09M▼ 33.7% | -117.86M▼ 28.0% | -116.91M▲ 0.8% | -695.98M▼ 495.3% | -883.08M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -4.15M▲ 0% | -10.84M▼ 161.1% | -43.34M▼ 299.8% | -68.9M▼ 59.0% | -92.09M▼ 33.7% | -117.86M▼ 28.0% | -116.91M▲ 0.8% | -695.98M▼ 495.3% | -883.08M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -161.05% | -299.82% | -58.98% | -33.67% | -27.98% | 0.81% | -495.29% | -644.61% |
Net Income (Continuing) | -4.15M | -10.84M | -43.34M | -68.9M | -92.09M | -117.86M | -116.91M | -695.98M | -883.08M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -14.60▲ 0% | -6.20▲ 57.5% | -26.60▼ 329.0% | -37.80▼ 42.1% | -46.60▼ 23.3% | -35.00▲ 24.9% | -34.00▲ 2.9% | -70.50▼ 107.4% | -2053.13▲ 0% |
EPS Growth % | - | 57.53% | -329.03% | -42.11% | -23.28% | 24.89% | 2.86% | -107.35% | -2659.41% |
EPS (Basic) | -14.60 | -6.20 | -26.60 | -37.80 | -46.60 | -35.00 | -34.00 | -70.50 | - |
Diluted Shares Outstanding | 283.02K | 1.86M | 1.86M | 1.86M | 1.98M | 3.36M | 3.44M | 9.87M | 430.12K |
Basic Shares Outstanding | 283.02K | 1.86M | 1.86M | 1.86M | 1.98M | 3.36M | 3.44M | 9.87M | 430.12K |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
VOR Balance Sheet
Vor Biopharma Inc. (VOR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 936K | 7.54M | 49.11M | 214.4M | 236.95M | 140.8M | 96.51M | 458.11M | 500.78M |
Cash & Short-Term Investments | 929K | 6.47M | 48.54M | 207.47M | 230.25M | 137.18M | 91.93M | 455.21M | 491.52M |
Cash Only | 929K | 6.47M | 48.54M | 119.8M | 57.71M | 31.36M | 81.95M | 396.49M | 169.87M |
Short-Term Investments | 0 | 0 | 0 | 87.67M | 172.54M | 105.81M | 9.98M | 58.72M | 321.65M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 205K | 100K | 2.09M | 2.34M | 475K | 380K | 2.9M | 9.25M |
Total Non-Current Assets | 71K | 2.29M | 26.8M | 28.19M | 62.42M | 69.03M | 46.38M | 6.02M | 5.97M |
Property, Plant & Equipment | 71K | 728K | 21.84M | 22.52M | 57.08M | 50.1M | 41.59M | 3.47M | 3.39M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 1.56M | 1.56M | 0 | 2.41M | 2.41M | 0 | 0 | 168K |
Other Non-Current Assets | 0 | 0 | 3.4M | 5.67M | 2.92M | 4.81M | 4.8M | 2.55M | 2.58M |
Total Assets | 1.01M▲ 0% | 9.83M▲ 875.8% | 75.91M▲ 672.5% | 242.59M▲ 219.6% | 299.37M▲ 23.4% | 209.83M▼ 29.9% | 142.89M▼ 31.9% | 464.13M▲ 224.8% | 506.75M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 875.77% | 672.52% | 219.58% | 23.4% | -29.91% | -31.9% | 224.81% | 685.38% |
Total Current Liabilities | 7.77M | 2.19M | 10.21M | 10.15M | 13.12M | 15.57M | 18.61M | 25.17M | 16.08M |
Accounts Payable | 38K | 693K | 2.36M | 1.54M | 1.77M | 815K | 1.5M | 5.13M | 1.04M |
Days Payables Outstanding | 693.5 | 2.78K | - | - | 72.19 | 85.19 | - | - | 25.17K |
Short-Term Debt | 4.46M | 0 | 863K | 0 | 0 | 3.83M | 0 | 280K | 307K |
Deferred Revenue (Current) | 1.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3.19M | 900K | 4.26M | 434K | 4.95M | 4.96M | 0 | 15.33M | 14.73M |
Current Ratio | 0.12x | 3.45x | 4.81x | 21.12x | 18.06x | 9.04x | 5.19x | 18.20x | 31.15x |
Quick Ratio | 0.12x | 3.45x | 4.81x | 21.12x | 18.06x | 9.04x | 5.19x | 18.20x | 31.15x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 17.43M | 16.17M | 35.64M | 43.53M | 27.61M | 603.27M | 641.09M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.63M |
Capital Lease Obligations | 0 | 0 | 17.43M | 16.17M | 35.64M | 31.83M | 27.61M | 2.72M | 5.53M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 11.7M | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 600.55M | 638.46M |
Total Liabilities | 7.77M | 2.19M | 27.64M | 26.33M | 48.76M | 59.1M | 46.23M | 628.44M | 657.17M |
Total Debt | 4.46M | 0 | 18.29M | 18.01M | 38.91M | 35.66M | 31.83M | 3M | 2.94M |
Net Debt | 3.53M | -6.47M | -30.25M | -101.79M | -18.79M | 4.3M | -50.12M | -393.49M | -166.93M |
Debt / Equity | - | - | 0.38x | 0.08x | 0.16x | 0.24x | 0.33x | - | -0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.45x |
Interest Coverage | -3.14x | -16.83x | - | - | - | - | - | - | - |
Total Equity | -6.77M▲ 0% | 7.64M▲ 212.9% | 48.27M▲ 531.8% | 216.26M▲ 348.0% | 250.61M▲ 15.9% | 150.72M▼ 39.9% | 96.66M▼ 35.9% | -164.31M▼ 270.0% | -150.42M▲ 0% |
Equity Growth % | - | 212.9% | 531.82% | 348.02% | 15.88% | -39.86% | -35.87% | -269.98% | -5383.33% |
Book Value per Share | -23.91 | 4.12 | 26.00 | 116.35 | 126.72 | 44.86 | 28.14 | -16.64 | -349.73 |
Total Shareholders' Equity | -6.77M | 7.64M | 48.27M | 216.26M | 250.61M | 150.72M | 96.66M | -164.31M | -150.42M |
Common Stock | 0 | 0 | 1K | 4K | 7K | 7K | 13K | 18K | 19K |
Retained Earnings | -7.05M | -17.89M | -61.22M | -130.12M | -222.22M | -340.08M | -456.99M | -1.15B | -1.37B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | -770K | -77K | 22K | 41K | -706K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VOR Cash Flow Statement
Vor Biopharma Inc. (VOR) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -2.66M | -9.86M | -36.29M | -69.14M | -85.14M | -100.29M | -99.66M | -142.71M | -149.89M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -270.35% | -268.26% | -90.52% | -23.14% | -17.79% | 0.63% | -43.2% | -209.37% |
Net Income | -4.15M | -10.84M | -43.34M | -68.9M | -92.09M | -117.86M | -116.91M | -695.98M | -883.08M |
Depreciation & Amortization | 20K | 91K | 605K | 1.43M | 2.52M | 3.49M | 3.53M | 2.89M | 2.09M |
Stock-Based Compensation | 116K | 172K | 1.34M | 4.32M | 10.7M | 13.36M | 9.85M | 18.91M | 16.98M |
Deferred Taxes | 289K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1M | 576K | 782K | 3.19M | 6.42M | 67K | 3.87M | 521.26M | 716.81M |
Working Capital Changes | 63K | 145K | 4.32M | -9.19M | -12.69M | 650K | 5K | 10.21M | -2.69M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 65K | 0 | 0 | 405K | 0 | 2.85M | 2.24M | 0 | 3.2M |
Cash from Investing | 0 | -748K | -4.16M | -91.65M | -94.09M | 71.01M | 96.86M | -48.8M | -311.81M |
Capital Expenditures | 0 | -748K | -4.16M | -3.89M | -8.46M | -1.07M | -229K | -941K | -758K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 799K | 799K |
Cash from Financing | 2.46M | 17.7M | 82.53M | 232.91M | 117.14M | 2.94M | 53.39M | 503.81M | 579.28M |
Debt Issued (Net) | 2.46M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 17.69M | 82.27M | 234.57M | 115.97M | 4.58M | 55.83M | 505.13M | 579.47M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 7K | 259K | -1.66M | 1.17M | -1.64M | -2.43M | -1.32M | -184K |
Net Change in Cash | -197K▲ 0% | 7.1M▲ 3702.0% | 42.07M▲ 492.9% | 72.12M▲ 71.4% | -62.09M▼ 186.1% | -26.35M▲ 57.6% | 50.59M▲ 292.0% | 312.29M▲ 517.3% | 119.99M▲ 0% |
Free Cash Flow | -2.66M▲ 0% | -10.6M▼ 298.5% | -40.45M▼ 281.5% | -73.04M▼ 80.6% | -93.61M▼ 28.2% | -101.36M▼ 8.3% | -99.89M▲ 1.5% | -143.65M▼ 43.8% | -150.65M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | -298.46% | -281.52% | -80.55% | -28.16% | -8.28% | 1.45% | -43.81% | -49.74% |
FCF per Share | -9.40 | -5.71 | -21.79 | -39.29 | -47.33 | -30.17 | -29.08 | -14.55 | -350.26 |
FCF Conversion (FCF/Net Income) | 0.64x | 0.91x | 0.84x | 1.00x | 0.92x | 0.85x | 0.85x | 0.21x | 0.17x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VOR Key Ratios
Vor Biopharma Inc. (VOR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -2483.16% | -155.02% | -52.09% | -39.45% | -58.74% | -94.52% | - | 87.31% |
| Return on Invested Capital (ROIC) | - | -338.81% | -78.13% | -40.47% | -48.87% | -90.18% | - | 22.61% |
| Debt / Equity | - | 0.38x | 0.08x | 0.16x | 0.24x | 0.33x | - | -0.02x |
| Interest Coverage | -16.83x | - | - | - | - | - | - | - |
| FCF Conversion | 0.91x | 0.84x | 1.00x | 0.92x | 0.85x | 0.85x | 0.21x | 0.17x |
Related:VOR Dividend History·VOR Revenue History·VOR Price History·VOR P/E History·VOR Financial Ratios·VOR Institutional Holders
VOR SEC Filings & Documents
Vor Biopharma Inc. (VOR) SEC filings — annual & quarterly reports (10-K, 10-Q)
VOR Frequently Asked Questions
Vor Biopharma Inc. (VOR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Vor Biopharma Inc. (VOR) grew revenue by 0.0% over the past year. Growth has been modest.
Vor Biopharma Inc. (VOR) reported a net loss of $883.1M for fiscal year 2025.
Dividend & Returns
Vor Biopharma Inc. (VOR) had negative free cash flow of $150.7M in fiscal year 2025, likely due to heavy capital investments.